Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.

Extranodal extension Human papillomavirus negative Oropharyngeal carcinoma Prognosis Radiology Staging

Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
03 2021
Historique:
received: 17 08 2020
revised: 26 11 2020
accepted: 24 12 2020
pubmed: 29 1 2021
medline: 18 11 2021
entrez: 28 1 2021
Statut: ppublish

Résumé

We evaluate the performance between the TNM-8 versus TNM-7 cN-classification and explore the relative prognostic contribution of radiologic extranodal extension (rENE) for HPV-negative oropharyngeal cancer (HPV-OPC). All HPV- OPC treated with IMRT between 2005 and 2016 were included. cENE was defined as unambiguous "fixation" of a neck mass or "skin involvement" on clinical examination. rENE was recorded by re-reviewing pre-treatment CT/MR. Disease-free survival (DFS) stratified by cENE or rENE were compared. Multivariable analyses (MVA) calculated the adjusted hazard ratio (aHR) for the separate cENE and rENE attributes and their combination. A refined cN-category incorporating both cENE and rENE parameters was proposed. The performance of the revision was compared to TNM-8 and TNM-7. Of 361 HPV- OPC, 97 were cN0 and 264 were cN+ with 48 cENE+ and 72 rENE+ respectively. Median follow-up was 5.4 years. The 3-year DFS was lower in cENE+ vs cENE-negative (cENE-) (23% vs 45%; aHR = 1.68, p = 0.008) and rENE+ vs rENE-negative (rENE-) patients (29% vs 45%; aHR = 1.44, p = 0.037). The cENE+/rENE+ subset had the worse DFS vs cENE-/rENE+ or cENE-/rENE- (24%/37%/46%, p = 0.005). We propose a refined cN-category wherein any cENE-/rENE+ case is reclassified one N-stratum higher while any cENE+ case remains cN3b. The stage schema with the refined N-categorization outperformed TNM-8, and both outperformed TNM-7. cENE and rENE are both prognostic but the cENE+/rENE+ subset has the worst outcome. The TNM-8 cN-categories improves outcome prediction compared to the TNM-7. Incorporation of rENE into TNM-8 cN-categories may further augment performance.

Sections du résumé

BACKGROUND/OBJECTIVES
We evaluate the performance between the TNM-8 versus TNM-7 cN-classification and explore the relative prognostic contribution of radiologic extranodal extension (rENE) for HPV-negative oropharyngeal cancer (HPV-OPC).
MATERIALS/METHODS
All HPV- OPC treated with IMRT between 2005 and 2016 were included. cENE was defined as unambiguous "fixation" of a neck mass or "skin involvement" on clinical examination. rENE was recorded by re-reviewing pre-treatment CT/MR. Disease-free survival (DFS) stratified by cENE or rENE were compared. Multivariable analyses (MVA) calculated the adjusted hazard ratio (aHR) for the separate cENE and rENE attributes and their combination. A refined cN-category incorporating both cENE and rENE parameters was proposed. The performance of the revision was compared to TNM-8 and TNM-7.
RESULTS
Of 361 HPV- OPC, 97 were cN0 and 264 were cN+ with 48 cENE+ and 72 rENE+ respectively. Median follow-up was 5.4 years. The 3-year DFS was lower in cENE+ vs cENE-negative (cENE-) (23% vs 45%; aHR = 1.68, p = 0.008) and rENE+ vs rENE-negative (rENE-) patients (29% vs 45%; aHR = 1.44, p = 0.037). The cENE+/rENE+ subset had the worse DFS vs cENE-/rENE+ or cENE-/rENE- (24%/37%/46%, p = 0.005). We propose a refined cN-category wherein any cENE-/rENE+ case is reclassified one N-stratum higher while any cENE+ case remains cN3b. The stage schema with the refined N-categorization outperformed TNM-8, and both outperformed TNM-7.
CONCLUSIONS
cENE and rENE are both prognostic but the cENE+/rENE+ subset has the worst outcome. The TNM-8 cN-categories improves outcome prediction compared to the TNM-7. Incorporation of rENE into TNM-8 cN-categories may further augment performance.

Identifiants

pubmed: 33508706
pii: S1368-8375(20)30603-5
doi: 10.1016/j.oraloncology.2020.105167
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105167

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Avinash Pilar (A)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada.

Eugene Yu (E)

Department of Neuroradiology and Head and Neck Imaging, Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Eugene.Yu@uhn.ca.

Jie Su (J)

Department of Biostatistics, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Susie.Su@uhnresearch.ca.

Brian O'Sullivan (B)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada; Department of Otolaryngology-Head & Neck Surgery, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Brian.Osullivan@rmp.uhn.ca.

Eric Bartlett (E)

Department of Neuroradiology and Head and Neck Imaging, Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Eric.Bartlett@uhn.ca.

John N Waldron (JN)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada; Department of Otolaryngology-Head & Neck Surgery, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: John.Waldron@rmp.uhn.ca.

Jolie Ringash (J)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada; Department of Otolaryngology-Head & Neck Surgery, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Jolie.Ringash@rmp.uhn.ca.

Anna Spreafico (A)

Division of Medical Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Anna.Spreafico@uhn.ca.

Aaron R Hansen (AR)

Division of Medical Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Aaron.Hansen@uhn.ca.

John de Almeida (J)

Department of Otolaryngology-Head & Neck Surgery, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: John.deAlmeida@uhn.ca.

Andrew Bayley (A)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Andrew.bayley@sunnybrook.ca.

Scott V Bratman (SV)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Scott.Bratman@rmp.uhn.ca.

John Cho (J)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: John.Cho@rmp.uhn.ca.

Meredith Giuliani (M)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Meredith.Giuliani@rmp.uhn.ca.

Andrew Hope (A)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Andrew.Hope@rmp.uhn.ca.

Ali Hosni (A)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Ali.Hosni@rmp.uhn.ca.

John Kim (J)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: John.Kim@rmp.uhn.ca.

Li Tong (L)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Li.Tong@rmp.uhn.ca.

Wei Xu (W)

Department of Biostatistics, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Wei.Xu@uhnresearch.ca.

Shao Hui Huang (SH)

Department of Radiation Oncology, The Princess Margaret Cancer Centre/University of Toronto, Canada; Department of Otolaryngology-Head & Neck Surgery, The Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Shaohui.Huang@rmp.uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH